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Abstract: Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is an aggressive malignancy
that occurs in young women, is characterized by recurrent loss-of-function mutations in the SMARCA4
gene, and for which effective treatments options are lacking. The aim of this study was to broaden
the knowledge on this rare malignancy by reporting a comprehensive molecular analysis of an
independent cohort of SCCOHT cases. We conducted Whole Exome Sequencing in six SCCOHT,
and RNA-sequencing and array comparative genomic hybridization in eight SCCOHT. Additional
immunohistochemical, Sanger sequencing and functional data are also provided. SCCOHTs showed
remarkable genomic stability, with diploid profiles and low mutation load (mean, 5.43 mutations/Mb),
including in the three chemotherapy-exposed tumors. All but one SCCOHT cases exhibited 19p13.2-3
copy-neutral LOH. SMARCA4 deleterious mutations were recurrent and accompanied by loss of
expression of the SMARCA2 paralog. Variants in a few other genes located in 19p13.2-3 (e.g., PLK5)
were detected. Putative therapeutic targets, including MAGEA4, AURKB and CLDN6, were found to
be overexpressed in SCCOHT by RNA-seq as compared to benign ovarian tissue. Lastly, we provide
additional evidence for sensitivity of SCCOHT to HDAC, DNMT and EZH2 inhibitors. Despite their
aggressive clinical course, SCCOHT show remarkable inter-tumor homogeneity and display genomic
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stability, low mutation burden and few somatic copy number alterations. These findings and
preliminary functional data support further exploration of epigenetic therapies in this lethal disease.
Keywords: ovary; small cell carcinoma; hypercalcemic; SMARCA4; SWI/SNF
1. Introduction
Small cell carcinoma of the ovary of the hypercalcemic type (SCCOHT) is a rare, highly aggressive
tumor that affects mainly young women (median age: 24 years). Prognosis is poor, as most patients
die within two years of diagnosis [1]. The histogenesis of SCCOHT remains unclear, although there is
increasing evidence in favor of a germ cell origin [2,3]. In addition, it has been proposed that SCCOHT
may represent the ovarian counterpart of malignant rhabdoid tumors [4].
While there is no international consensus regarding the optimal treatment of SCCOHT, it usually
involves multimodal chemotherapy, radical surgery and possibly, radiotherapy [5]. However,
no randomized studies have been conducted to date and the available data consist of case reports or
small retrospective series with heterogeneous management strategies. The only prospective clinical
study in SCCOHT, a multicenter phase II trial conducted at Institut Gustave Roussy, tested combination
chemotherapy (PAVEP: cisplatin, adriamycin, vepeside and cyclophosphamide) followed by radical
surgery and high dose chemotherapy with autologous stem cell transplant, and demonstrated a three
year survival rate of 49% among 27 SCCOHT patients [6]. This shows that even with intensive regimens,
prognosis remains dismal, and that despite frequent initial response to chemotherapy, relapses are
almost inevitable and tend to be refractory to second line chemotherapy.
The literature describing the genomic features of SCCOHT was scarce until 2014, when four
groups identified loss-of-function mutations in SMARCA4 (Brahma-related gene 1, BRG1) as a highly
recurrent event in SCCOHT [3,4,7,8]. SMARCA4 encodes one of the two possible catalytic subunits of
the Switch/Sucrose Non-Fermentable (SWI/SNF) chromatin-remodeling complex. Others have since
confirmed this finding, with SMARCA4 mutations being found in over 90% of cases [9]. Nevertheless,
effective treatment options to target this rare and lethal disease are still lacking.
We aimed to conduct an integrated genomic analysis of an independent cohort of SCCOHT
by WES, RNA-Seq and aCGH to check for the presence of additional recurrent genomic alterations,
which could allow the proposal of alternative treatment strategies.
2. Materials and Methods
2.1. Patients and Samples
Fresh-frozen tumor samples from 8 patients with SCCOHT were identified from the tumor banks
of Institut Gustave Roussy, Cochin University Hospital, Grenoble University Hospital, Longjumeau
University Hospital and Hôpital de la Croix Rousse. Central review for histological diagnosis was
conducted by an expert pathologist. Matched blood samples were available for 6 patients. All patients
provided written informed consent allowing the use of their tumor and non-tumor tissues for research.
Approval from the hospital’s institutional review board was obtained for the study and funding was
obtained via an educational grant awarded by the Foundation Gustave Roussy (local IRB approval
RT12014). In addition, a further 33 formalin-fixed paraffin-embedded (FFPE) SCCOHT samples
were available for validation studies. Tumors were obtained with patient consent and all data
were anonymized.
2.2. DNA Extraction
DNA was extracted from fresh-frozen tumors and matched blood using the AllPrep DNA Mini
Kit (Qiagen, Valencia, CA, USA) according to the manufacturer’s instructions, and quantified using
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Qubit (Thermo Fisher Scientific, Waltham, MA, USA). DNA integrity was measured using an Agilent
BioAnalyzer (Agilent, Santa Clara, CA, USA).
2.3. Whole Exome Sequencing (WES)
Exome capture and library preparation were performed using the Sure Select Human All Exome
v5 and SureSelectXT kits, respectively (Illumina, Agilent Technologies, CA, USA). Sequencing was done
on matched tumor and normal samples using HiSeq2000 (Illumina, San Diego, CA, USA) in paired-end
mode with a mean target depth of 100X. Reads were mapped using BWA-MEM (V0.7.5a-r405) [10]
against reference genome hg19. Analysis of coverage was done using GATK (2.7.4-g6f46d11) [11]
Depth of Coverage. Local realignment was performed around indels using GATK Realigner Target
Creator and GATK Indel Realigner.
Variants were called with Varscan 2 [12], using hg19 as the reference genome and requiring a
minimum tumor read depth of 6, a minimum somatic read depth of 8 and a minimum tumor allelic
frequency of 0.10. Results were then annotated using SnpEff (4.3t) [13] and SnpSift (4.3t) [14] with
dbSNP (v150_hg19) (http://www.ncbi.nlm.nih.gov/SNP/) and dbNSFP (v2.9) [15].
Tumor mutation burden (TMB) was calculated based on the number of non-synonymous,
somatic-only mutations (single nucleotide variants and small insertions/deletions) with a somatic
p-value threshold at <0.05 per megabase in coding regions considered as having sufficient coverage
(6× in tumors and 8× in matched normal samples) by the variant caller [16].
Specific germline mutation analysis could not be performed, because a clause pertaining to
germline testing was not included in the consent form at the time when each patient’s consent
was obtained.
2.4. Oligonucleotide CGH Microarrays
DNA was labeled and hybridized, and CGH microarray analysis was performed as detailed in
Supplementary Methods. Resulting log2 (ratio) values were segmented using the CBS [17] algorithm
implementation from the DNA copy package for R. Aberration status calling was automatically
performed for each profile according to its internal noise (absolute variation of log2 (ratio) values
across consecutive probes on the genome). All genomic coordinates were established on the UCSC
Homo sapiens genome build hg19 [18].
2.5. SMARCA2 Promoter Sequencing
Sanger sequencing of SMARCA2 promoter polymorphism sites was performed
on DNA from 8 fresh-frozen SCCOHT tumor samples and 2 cell lines (BIN67 and
SCCOHT-1). The following primers were used: for the −741 site,
Forward—TTTGGAAGCTTGCAGTCCTT, Reverse—CCGGCTGAAACTTTTTCTCC; for the−1321 site,
Forward—CCCAGTTGCTCAAATGGAGT, Reverse—AGGTCGGTGTTTGGTGAGAC. After PCR,
10 uL from a 50 uL reaction were run on a 2% agarose gel to confirm amplification. The remaining
PCR reaction was purified using the Qiagen QIAquick PCR Purification Kit, quantified and 10 ng
together with 25 pmol of either the Forward or the Reverse primer were submitted to Genewiz (USA)
for Sanger sequencing.
2.6. RNA Sequencing (RNA-Seq), Real-Time RT-PCR and Differential Expression Analysis
RNA-seq was performed on RNA from 8 fresh-frozen SCCOHT tumors, on a HiSeq2000 sequencer,
using paired-end 2 × 76 bp stranded mode. Raw reads were mapped against human genome (hg19)
with the STAR (v2.3.0) 2-pass method [19] and potential duplicates were marked using Picard tools
(http://picard.sourceforge.net/). Remaining reads were split into exon segments and STAR mapping
qualities were reassigned in order to fit GATK (v3.2-2) Indel Realignment requirements [11,20,21].
After local realignment around indels, a base quality score recalibration (BQSR) process was applied,
and the variant calling step was done with HaplotypeCaller in RNA-seq mode. Finally, the raw variants
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list obtained above was filtered on a Phred-scaled p-value using Fisher’s exact test to detect strand bias
(FS > 30.0) and Variant Confidence/Quality by Depth (QD < 2.0) values. RNA-seq data were also used
to identify variants following Broad Institute Best Practices.
Differential RNA-seq gene expression analysis between SCCOHT samples and benign ovarian
tissue from the GTEx dataset was performed using rank-normalized expression values and is detailed
in Supplementary Methods.
Quantitative real-time polymerase chain reaction (real-time RT-PCR) analyses to assess the
expression levels of SMARCA2 were performed on RNA from 8 fresh-frozen SCCOHT tumors and
from the BIN-67 cell line, as detailed in Supplementary Methods.
2.7. Immunohistochemistry
SMARCA4 (BRG1) and SMARCA2 (BRM) protein expression was assessed by
immunohistochemistry (IHC) using the anti-BRG1 (Santa Cruz, sc-10768) and anti-BRM (Abcam,
ab15597) antibodies at dilutions of 1/200 and 1/50, respectively. After paraffin removal and hydration,
slides were immersed in 10 mM citrate buffer pH 6 for 30 min for antigen retrieval, incubated
with primary antibody for one hour at room temperature, washed and incubated with biotinylated
secondary antibody for 30 min at room temperature. Streptavidin-biotin amplification (VECTASTAIN
Elite ABC Kit) was then performed for 30 min, followed by peroxidase/diaminobenzidine substrate
chromogenic reaction. IHC for SOX2 was performed using a Bond III automated immunostainer and
the Bond Polymer Refine detection system (Leica Microsystems, IL, USA). Slides were deparaffinized
and heat-mediated antigen retrieval was performed using the Bond Epitope Retrieval 2 solution at
pH 9 (H2). The anti-SOX2 antibody clone D6D9 (Cell Signaling Technology) was used at 1/100 dilution.
2.8. Cell Culture and Viability Assays
These methods are available in the Supplementary Methods section.
3. Results
3.1. Clinical Data and Mutational Profiles of SCCOHT: A General Overview
The available clinical data are summarized in Supplementary Table S1. The cohort comprised
eight patients with a mean age at diagnosis of 31 years (range, 14–40), all of whom were diagnosed with
stage III–IV tumors (Figure 1A). Three patients had received chemotherapy prior to sample collection.
After a median follow-up of 10 months (range, 3–36 months), seven patients died of disease, while one
patient achieved remission and remained disease-free at 36 months follow-up. Histomorphology was
reviewed by an expert pathologist (C.G.) and was confirmed to be consistent with SCCOHT for all
cases (Figure 1B, Supplementary Figure S1).
WES was conducted on six tumor-normal pairs. The mean depth of coverage was 109X, with at
least 98% of the targeted exome covered by at least 10 reads and 95% showing a read quality score
(QC) ≥30 (Supplementary Table S2).
The tumor mutation burden (TMB), calculated as specified in the Methods section, was low,
with a median of 5.60 mutations/Mb (mean, 5.43 mutations/Mb; range: 3.56–6.42). Very few genes
showed somatic-only mutations in more than one sample (Supplementary Table S3). These included:
SMARCA4 (three cases, variants in coding regions were predicted to be deleterious and detailed
hereafter); HMCN2 (three cases, missense variants were predicted as benign by Polyphen-2); ADGRV1
(two cases—one stop gain and one missense variant—both heterozygous), FANCD2 (two cases, splice
region variant predicted to be of low functional impact by the SnpEff tool), and LRRK2 (two cases,
intronic variants).
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Figure 1. An overview of mutational profiles of SCCOHT. (A) Clinical characteristics of the cohort 
and tests performed. (B) Representative histopathology of a SCCOHT case from this cohort (IGR-04), 
including rhabdoid features; hematoxylin-eosin-saffron, scale bar: 50 μm. (C) Combined analysis of 
somatic-only and LOH-related alterations: an overview of the 14 genes altered in at least 50% of 
samples. (D) Breakdown of variants detected in the 14 recurrently altered genes, including 
classification as known polymorphisms (Genome Aggregation Database v.2.1.1) and Polyphen-2 
functional prediction scores. N/A: not available. P/D: possibly or probably damaging. The variants 
for which functional impact cannot be ruled out are explicitly listed. (E) Type and localization of the 
mutations found by WES in the SMARCA4 gene; * indicates that this identical mutation was found in 
two independent patients. 
In order to also account for alterations that may be related to an LOH event, we performed a 
second analysis using the following criteria: mutant allele frequency higher in tumor than in normal 
Figure 1. An overview of mutational profiles of SCCOHT. (A) Clinical characteristics of the cohort
and tests performed. (B) Representative histopathology of a SCCOHT case from this cohort (IGR-04),
including rhabdoid features; hematoxylin-eosin-saffron, scale bar: 50 µm. (C) Combined analysis of
somatic-only and LOH-related alterations: an overview of the 14 genes altered in at least 50% of samples.
(D) Breakdow of variants detected in the 14 recurrently altered genes, including classification as
known polymorphisms (Geno e Aggregation Database v.2.1.1) and Polyphen-2 functional prediction
scores. N/A: not available. P/D: possibly or probably damaging. The variants for which functional
impact cannot be ruled out are explicitly listed. (E) Type and localization of the mutations found by WES
in the SMARCA4 gene; * indicates that this identical mutation was found in two independent patients.
In order to also account for alterations that may be related to an LOH event, we performed a
second analysis using the following criteria: mutant allele frequency higher in tumor than in normal
tissue; somatic p-value < 0.001 (Fisher’s exact test); and location in a coding region. Using these
cut-offs, 500 variants in 335 genes were retained. Among those, fourteen genes were altered in at least
50% of cases (“recurrently altered” genes, Figure 1D,E, Supplementary Tables S4 and S5); importantly,
all of these genes were located in 19p13.2-3 and all variants were detected at high allelic frequencies
(mean variant allele fraction: 0.88, range: 0.74–0.93), suggesting a recurrent loss-of-heterozygosity
(LOH) event in 19p13.2-3. The majority (56/64) of these variants were known polymorphisms (variant
frequency in the general population ≥1%) (Figure 1D, Supplementary Tables S4 and S5) and 45/64
were classified as benign by the Polyphen-2 classifier. Variants that were not polymorphisms and that
were classified as potentially or probably damaging, or for which functional prediction scores were not
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available (Figure 1D) included: four variants in SMARCA4 in five patients (described in detail hereafter;
Figure 1E), the p.G223V variant in PLK5 (one patient), the p.R220H variant in ACTL9 (one patient)
and the c.4208delT frameshift in ABCA7 (one patient); all of these variants were Sanger-verified
(Supplementary Table S4).
Lastly, no mutations in the following cancer-related genes were observed in any of the SCCOHT
tumors, even at low allelic fractions: TP53, KRAS, PIK3CA, PTEN, BRAF, EGFR, AKT1, CDKN1A (p21)
or ERBB2.
3.2. Inactivating SMARCA4 Mutations and Related Findings
In line with previous studies, SMARCA4 (Brahma-related gene 1, BRG1) was mutated by WES
in 5/6 (83%) SCCOHT samples in our series (Figure 1C,D). The mean allelic fraction was high (0.86)
and consistent with homozygous alterations. The encountered SMARCA4 mutations were p.N774
frameshift, c.3216-1G>T (splice), p.R1077* stop gain (this mutation was identical in two patients) and
p.K1081E (predicted as deleterious by the Polyphen-2 classifier). These variants have been previously
reported in Le Loarer et al. [22], as part of the control cohort. All mutations occurred upstream of the
SNF2-ATP coupling domain and the bromodomain, suggesting that the functional impact would be a
loss of protein expression or function (Figure 1C). In line with those genomic findings, we observed
loss of SMARCA4 (BRG1) protein expression by IHC in all cases that displayed SMARCA4 mutations
(Figure 2A).
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type. Tumor harboring concomitant ARID1A and ARID1B mutations (IGR-03). (B) Real-time 
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(BIN-67); expression levels are normalized to three housekeeping genes 
(YWHAZ/GUSB/HPRT1). (C) Western blot showing expression of several SWI/SNF 
Figure 2. SMARCA4 and SMARCA2 expression in SCCOHT. (A) Representative SMARCA4 and
SMARCA2 immunohistochemistry in SMARCA4 mutated SCCOHT and in the on SMARCA4
wild-type. Tumor harboring concomitant ARID1A and ARID1B mutations (IGR-03). (B) Real-time
RT-PCR for SMARCA2 in patient tumor samples from this study and in a SCCOHT cell line (BIN-67);
expression levels are normalized to three housekeeping genes (YWHAZ/GUSB/HPRT1). (C) Western blot
showing expression of several SWI/SNF subunits in SCCOHT cell lines (BIN-67, SCCOHT-1) compared
to MRT (G401, MON, TTC709), SMARCA4-mutated lung cancer (H1299), high-grade endometrioid
adenocarcinoma of the ovary (SKOV3) and neuroendocrine small cell lung cancer (DMS79) cell lines.
(D) Results of Sanger sequencing of the SMARCA2 promoter insertional polymorphism sites, and an
example of a heterozygous polymorphism status (−1321 site) in BIN-67 cells. (E) Representative IHC
for SOX2 in SCCOHT and a positive control (SOX2-positive MRT) in patient FFPE tumor samples.
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One tumor (IGR-03) diagnosed as SCCOHT did not exhibit a SMARCA4 mutation but instead,
harbored concomitant and potentially biallelic loss-of-function alterations in two other SWI/SNF genes:
ARID1A (two frameshifts—p.Q555fs and p.T1004fs) and ARID1B (stop gained R1944*). Consequently,
SMARCA4 (BRG1) protein expression in this tumor was retained by IHC (Figure 2A).
Of note, one case (IGR-01) also showed a p.Arg635* stop gain in the SMARCA1 gene, in addition
to a deleterious SMARCA4 mutation.
3.3. SMARCA2 Loss of Expression in SCCOHT
Recent studies have shown that in addition to SMARCA4 inactivation, SCCOHT exhibit a loss
of expression of the SMARCA2 paralog [23]. In our cohort, all SMARCA4-mutated SCCOHT (n = 5)
showed low/absent SMARCA2 transcript levels by real-time RT-PCR and complete absence of the
SMARCA2 (BRM) protein by IHC (Figure 2A,B), in keeping with previous studies. Combined loss
of SMARCA4 and SMARCA2 expression in SCCOHT was also confirmed in our extended series of
33 FFPE SCCOHT, as we recently reported [24]. No SMARCA2 loss-of-function mutations or deletions
were found by WES. In the one SMARCA4 wild-type tumor (IGR-03) which showed concomitant
ARID1A and ARID1B mutations, SMARCA2 expression was higher at the mRNA level (real-time
RT-PCR) than in SMARCA4 mutated samples, and interpreted as ambiguous/low at the protein level
(IHC).
We also validated loss of SMARCA4 and SMARCA2 protein expression in two SCCOHT cell lines,
BIN-67, and SCCOHT-1, by immunoblotting (Figure 2C). Notably, we observed that expression of other
SWI/SNF subunits was retained, in line with a recent study by Pan et al. characterizing the presence of
a residual SWI/SNF complex with altered functions in SCCOHT tumor cells [25].
The existence of homozygous insertional polymorphisms of the SMARCA2 promoter, located
−741 bp and −1321 bp from the transcription start site, has previously been linked to loss of
SMARCA2 expression in lung cancer [26]. Thus, we performed Sanger sequencing of the −741
and −1321 promoter sites in eight SCCOHT tumor samples and in two SCCOHT cell lines (BIN-67 and
SCCOHT-1). One tumor and one cell line (SCCOHT-1) were homozygous for the −741 polymorphism,
another tumor was homozygous for the −1321-promoter site polymorphism, and all other cases
displayed a heterozygous−741 and−1321 polymorphism site status (Figure 2D). Overall, we concluded
that a homozygous polymorphism site status in the SMARCA2 promoter, previously described in lung
cancer, was not a feature of SCCOHT.
Concomitant loss of SMARCA4 and SMARCA2 expression is also a feature of SMARCA4-deficient
thoracic sarcomas (SMARCA4-DTS) and of a subset of malignant rhabdoid tumors (MRTs) [22,27,28].
SMARCA4-DTS have been reported to consistently show strong expression of the neural stem cell
transcription factor SOX2 [27]. To verify whether the same was true for SCCOHT, 10 FFPE SCCOHT
tumors were tested by IHC. Six showed no SOX2 staining (Figure 2E), two showed scattered positive
cells and only two showed focal staining (<10% of tumor surface).
3.4. Validation of the p.G223V PLK5 Variant in a Larger Series of SCCOHT Samples
PLK5 is the most recently described member of the Polo-Like Kinase family (PLK) family and has
been implicated in involved in DNA damage response and cell cycle checkpoint control [29]. Given the
presence of PLK5 variants in a subset of SCCOHT detected by WES, the potentially damaging p.G223V
variant was chosen for further Sanger validation in an extended cohort of 33 FFPE SCCOHT tumors
(Supplementary Table S6). Overall, this mutation was detected in 3/33 (9%) of SCCOHT, suggesting
that although it may be present in SCCOHT, it is not a highly recurrent event.
3.5. Somatic Copy Number Alterations (SCNAs) in SCCOHT
Eight fresh-frozen tumors were available for aCGH analysis. As shown in Figure 3B, the aCGH
profiles of seven of the eight tumors showed remarkable genomic stability, with few SCNAs. The one
tumor exhibiting genomic instability (IGR-07) harbored a loss of BRCA2, interpreted as heterozygous
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[log2 (ratio) = −0.4]. No SCNA was common to ≥50% of tumors, however, 16 recurrent gains were
shared by at least three of the eight tumors (Table 1). Four of these genes showed a log2 (ratio) > 2.3,
which represents a five-fold increase in copy number, suggestive of amplification: SHMT2, NDUFA4L2,
LRP1 and NXPH4.Cells 2020, 9, x FOR PEER REVIEW 9 of 18 
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Table 1. Recurrent Gains Shared by at Least three of eight Tumors. Aberrant SCNAs Were Defined as
log2 (ratio) < −1 or > 1.
Localization Gene Symbol Description Mean Log2Ratio
12q12-q14 SHMT2 Serine hydroxymethyltransferase 2 (mitochondrial) 2.33
12q13.3 NDUFA4L2 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4-like 2 2.33
12q13.3 NXPH4 Neurexophilin 4 2.33
12q13.3 LRP1 Low density lipoprotein receptor-related protein 1 2.33
14q32.2 BEGAIN Brain-enriched guanylate kinase-associated 2.23
14q32.2 LINC00523 Long intergenic non-protein coding RNA 523 2.23
16q24 CBFA2T3 Core-binding factor, runt domain, alpha subunit 2; translocated to, 3 1.40
16q24 APRT Adenine phosphoribosyltransferase 1.40
16q24.3 ACSF3 Acyl-CoA Synthetase Family Member 3 1.40
16q24.3 CTU2 Cytosolic thiouridylase subunit 2 homolog (S. pombe) 1.40
16q24.3 GALNS Galactosamine (N-acetyl)-6-sulfate sulfatase 1.40
16q24.3 MIR4722 MicroRNA 4722 1.40
16q24.3 PABPN1L Poly(A) binding protein, nuclear 1-like (cytoplasmic) 1.40
16q24.3 CDT1 Chromatin licensing and DNA replication factor 1 1.40
16q24.3 PIEZO1 Piezo-type mechanosensitive ion channel component 1 1.40
16q24.3 TRAPPC2L Trafficking protein particle complex 2-like 1.40
3.6. Copy-Neutral Loss-of-Heterozygosity (CN-LOH) at the 19p13.2-3 Locus
WES revealed recurrent loss-of-heterozygosity (LOH) at the 19p13.2-3 region in five of six tumors
and nominated the smallest common LOH region as Chr19:373.916-11.465.316 (Figure 3A). We mapped
this “common LOH-region” by aCGH and, as shown in Figure 3B,C, confirmed that no copy number
losses were present in this region, thus supporting the presence of a recurrent copy neutral-LOH
(CN-LOH) event (Figure 3D).
3.7. Gene Expression Profiles of SCCOHT
To compare gene expression data in SCCOHT with our genomic findings, we conducted
RNAseq-based differential expression analysis comparing six SMARCA4-mutated SCCOHT cases from
our cohort and five samples of benign ovarian tissue from premenopausal women from the GTEx
dataset. The analysis was conducted on rank-normalized gene expression values to reduce batch effect
(Supplementary Table S7). As expected, SMARCA2 expression was significantly lower in SCCOHT
than in benign ovarian tissue, with mean rank-normalized expression values of 0.50 vs. 0.95, log2 fold
change = −0.92 and padj = 0.015. No statistically significant difference in SMARCA4 expression was
detected, possibly due to low SMARCA4 expression in two of the benign ovarian samples.
None of the four genes that showed recurrent amplifications in SCCOHT (NDUFA4L2, SHMT2,
NXPH4, LRP) was significantly overexpressed in this analysis. PLK5 showed very low expression values
in both groups (mean rank-normalized expression values of 0.18 and 0.17, respectively). SCCOHT also
did not show significant overexpression of SOX2 (consistently with our IHC data) or of PTHLH
(which encodes Parathyroid Hormone-Related Protein, previously postulated to cause hypercalcemia
in a subset of SCCOHT).
Differential expression analysis also allowed the nomination of some genes potentially
overexpressed in SCCOHT. Overall, ~1900 significantly differentially expressed genes showed
log2 fold change > 1 or < −1 and padj < 0.05 (Supplementary Table S8). The most significantly
overexpressed genes (top 100) included: cancer-testis antigens (e.g., MAGEA4, which was also
the most significantly overexpressed gene, MAGEA9, DSCR8, SYCE3); the AURKB gene, encoding
an Aurora kinase involved in mitotic progression; the tyrosine kinase receptor gene ERBB4 (HER4);
genes encoding metalloproteinases (e.g., MMP10, MMP9, MMP1); genes related to neural development
(e.g., NCAM2, NTS, ATCAY, CBLN2); embryonic stem cell genes (CLDN6, which encodes an embryonic
cell junction protein); and germ cell markers (SALL4) (Figure 4A, Supplementary Table S8). Conversely,
the expression of some genes known to be highly expressed in benign ovarian tissue was significantly
lower in SCCOHT (e.g., INHA, FOXL2, AMHR2). Gene Set Enrichment Analysis (GSEA) (Figure 4B,
Supplementary Table S9) showed that gene sets significantly enriched in SCCOHT included those
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related to E2F targets and cell cycle progression, DNA repair, activation of oncogenic pathways (KRAS,
MYC, mTORC1), as well as gene sets related to SMARCB1 (SNF5) knockdown, consistent with a
deregulated SWI/SNF complex.
Cells 2020, 9, x FOR PEER REVIEW 11 of 18 
 
 
Figure 4. An overview of transcriptomic profiles of SCCOHT. (A) Graphic heatmap representation of 
rank-normalized expression values for selected, most significantly deregulated genes in the 
differential expression analysis between SCCOHT and benign ovarian tissue (GTEx). (B) Selected 
GSEA results for the differential expression analysis between SCCOHT and benign ovarian tissue 
(GTEx). (C) Selected GSEA results for the differential expression analysis between chemotherapy-
exposed SCCOHT samples (IGR-01, IGR-04, IGR-06) and chemotherapy-naïve samples (IGR-02, IGR-
05, IGR-08). 
3.8. Genomic and Transcriptomic Profiles of Chemotherapy-Naïve Versus Chemotherapy-Exposed SCCOHT 
SCCOHT are characterized by initial chemosensitivity, but almost invariably relapse. Thus, we 
compared mutation profiles in the three treatment-naïve and three chemotherapy-exposed tumors, 
to determine whether some alterations were enriched in post-treatment samples. The chemotherapy 
regimens received by patients IGR01, IGR04 and IGR06 prior to sample collection/surgery were 
VIP/Doxorubicin, BEP/ PAVEP and EP/PAVEP, respectively (Supplementary Table S1). 
Tumor mutation burden was not significantly higher in the three post-chemotherapy samples 
than in the three chemo-naïve ones: mean, 4.98 non-synonymous mutations/Mb (range: 3.56–6.42) 
and mean, 5.87 mutations/Mb (range, 5.21–6.42), respectively (p = 0.38, unpaired t-test). Among 
somatic-only mutations (i.e., mutations not imputable to an LOH event), two genes were altered in 
at least two post-chemotherapy samples, but not in chemo-naïve samples: ADGRV1 (IGR-01 and IGR-
06—one stop gain and one missense alteration) and FANCD2 (IGR-04 and IGR-06—splice region 
variant predicted to be of low functional impact by the SnpEff tool). No SCNAs were differentially 
detected in the chemotherapy-exposed versus chemotherapy-naïve tumors (data not shown). 
RNAseq-based differential expression analysis between the chemotherapy-exposed and the 
chemotherapy-naïve samples did not identify any significantly differentially expressed genes (data 
not shown). However, when analyzing ranked genes in their totality, GSEA analysis revealed several 
gene sets with significant positive or negative enrichment (Supplementary Table S10). Among these, 
there was a positive enrichment of the gene set reflecting genes upregulated upon overexpression of 
Eukaryotic Translation Initiation Factor 4E (eEIF4E), a positive enrichment of gene sets 
SCCOHT Benign ovary (GTEx)A. B.
C.
EIF4E_UP HALLMARK KRAS_SIGNALING_UP
HALLMARK E2F_TARGETS
SNF5_DN.V1_UP
NES=3.05
NOM p-val=0
FDR q-val=0
NES=1.79
NOM p-val=0
FDR q-val=0.005
En
ric
hm
en
t s
co
re
En
ric
hm
en
t s
co
re
En
ric
hm
en
t s
co
re
HALLMARK KRAS_SIGNALING_UP
NES=1.34
NOM p-val=0
FDR q-val=0.08
NES=1.62
NOM p-val=0.002
FDR q-val=0.06
NES=-1.44
NOM p-val=0.003
FDR q-val=0.06
En
ric
hm
en
t s
co
re
maxmin
median
SCCOHT vs. benign ovary (GTEx)
Chemotherapy-exposed vs. chemotherapy-naive SCCOHT 
Figure 4. An overview of transcriptomic profiles of SCCOHT. (A) Graphic heatmap representation
of rank-normalized expression values for selected, most significantly deregulated genes in the
differential expression analysis between SCCOHT and benign ovarian tissue (GTEx). (B) Selected GSEA
results for the differential expression analysis between SCCOHT and benign ovarian tissue (GTEx).
(C) Selected GSEA results for the differential expression analysis between chemotherapy-exposed
SCCOHT samples (IGR-01, IGR-04, IGR-06) and chemotherapy-naïve samples (IGR-02, IGR-05, IGR-08).
3.8. Genomic and Transcriptomic Profiles of Chemotherapy-Naïve Versus Chemotherapy-Exposed SCCOHT
SCCOHT are characterized by initial chemosensitivity, but almost invariably relapse. Thus,
we compared mutation profiles in the three treatment-naïve and three chemotherapy-exposed tumors,
to determine whether some alterations were enriched in post-treatment samples. The chemotherapy
regimens received by patients IGR01, IGR04 and IGR06 prior to sample collection/surgery were
VIP/Doxorubicin, BEP/ PAVEP and EP/PAVEP, respectively (Supplementary Table S1).
Tumor mutation burden was not significantly higher in the three post-chemotherapy samples than
in the three chemo-naïve ones: mean, 4.98 non-synonymous mutations/Mb (range: 3.56–6.42) and mean,
5.87 mutations/Mb (range, 5.21–6.42), respectively (p = 0.38, unpaired t-test). Among somatic-only
mutations (i.e., mutations not imputable to an LOH event), two genes were altered in at least two
post-chemotherapy samples, but not in chemo-naïve samples: ADGRV1 (IGR-01 and IGR-06—one stop
gain and one missense alteration) and FANCD2 (IGR-04 and IGR-06—splice region variant predicted
to be of low functional impact by the SnpEff tool). No SCNAs were differentially detected in the
chemotherapy-exposed versus chemotherapy-naïve tumors (data not shown).
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RNAseq-based differential expression analysis between the chemotherapy-exposed and the
chemotherapy-naïve samples did not identify any significantly differentially expressed genes (data not
shown). However, when analyzing ranked genes in their totality, GSEA analysis revealed several gene
sets with significant positive or negative enrichment (Supplementary Table S10). Among these, there was
a positive enrichment of the gene set reflecting genes upregulated upon overexpression of Eukaryotic
Translation Initiation Factor 4E (eEIF4E), a positive enrichment of gene sets downregulated upon
KRAS overexpression, and a negative enrichment of genes upregulated upon KRAS overexpression
(Figure 4C).
3.9. Epigenetic Vulnerabilities of SCCOHT Associated with SWI/SNF Deregulation
In a recent study, Pan et al. have shown that the loss of catalytic SWI/SNF activity in SCCOHT
largely alters SWI/SNF functions as an epigenetic regulator [25]. To assess the putative sensitivity of
SCCOHT to currently available epigenetic treatments, cell lines with differing SMARCA4 genotypes
were treated with the histone deacetylase inhibitor trichostatin A (TSA) and the DNA methyltransferase
inhibitor 5′-dAZAC. The SCCOHT cell line BIN-67, which harbors an inactivating SMARCA4
mutation and shows complete loss of SMARCA2 expression (Figure 2C), was exquisitely sensitive
to 5′-dAZAC and TSA at sub-nanomolar concentrations (Figure 5A,B). Conversely, the H1299 lung
cancer cell line, which carries a SMARCA4 mutation, but shows retained SMARCA2 expression
(SMARCA4-/SMARCA2+), and the ovarian high-grade endometrioid adenocarcinoma cell line SKOV3
(SMARCA4+/SMARCA2+) were completely resistant to 5′-dAZAC and 100-fold less sensitive to TSA
than BIN-67 (Figure 5A,B).
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Many studies suggest an antagonistic relationship between the SWI/SNF complex and Polycomb
proteins, such as Enhancer of Zest 2 (EZH2) [30]. Combined loss of SMARCA4 and SMARCA2 in
SCCOHT cell lines may induce an oncogenic dependency on EZH2 activation [31] and confer extreme
sensitivity to EZH2 inhibitors in vitro and in vivo [32]. Based on this rationale, we enrolled a patient
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with SMARCA4-mutated SCCOHT in a phase I trial of tazemetostat (EPZ-6438), a highly selective EZH2
inhibitor [33]. This 25-year-old patient initially presented with stage IV SCCOHT treated with surgery,
combination platinum-based chemotherapy followed by high dose consolidation and autologous stem
cell rescue (Figure 5C). Unfortunately, she relapsed within eight weeks and was, therefore, enrolled
in the EZH2 inhibitor clinical trial. She presented partial response (RECIST 1.1) after four months of
treatment and remained progression-free for eight months. Although the clinical benefit was relatively
short, the degree of response in this patient with highly chemo-resistant disease supports further
investigation of epigenetic strategies in SCCOHT.
4. Discussion
SCCOHT are rare tumors that occur in young women and their prognosis remains poor, despite
aggressive multimodal therapy. We present an integrated molecular characterization of additional
cases of SCCOHT from an independent cohort.
Intriguingly, our findings and the previously published data show that these aggressive tumors
carry a diploid DNA content, which is a rare phenomenon in a highly lethal malignancy [34,35].
In addition, we show that SCCOHT have a very low mutation load (mean, 5.43 mut/Mb) and lack
mutations in genes most altered across various cancer types. Collectively, these observations support the
hypothesis that SCCOHT are largely driven by epigenetic deregulation and not by genomic instability.
Importantly, our results underscore marked inter- and intra-tumor homogeneity of SCCOHTs.
Combined WES and aCGH analysis revealed a recurrent copy-neutral LOH (CN-LOH) at the
19p13.2-3 locus. CN-LOH can account for inactivation of tumor suppressor genes and likely implicates
the loss of the normal allele and duplication of the mutated copy. Notably, 19p LOH has previously
been detected in SCCOHT by WES [4,36], but our results provide additional evidence for a copy-neutral
nature of this event. Of note, telomeric CN-LOH has been linked to meiotic errors occurring during
cross-over [37], which could be in line with the postulated germ cell origin of SCCOHT tumors [2,3],
although further studies are needed to support this hypothesis. The 19p CN-LOH associated with
inactivating SMARCA4 mutations has also been reported in non-small cell lung cancer [38].
In line with previous studies, we found that SMARCA4 mutations were present in all but
one SCCOHT (5/6) in our series. SMARCA4 encodes one of the enzymatic (ATP-ase) subunits of
mammalian SWI/SNF, a chromatin remodeling complex which directs nucleosomes and modulates
gene expression. The importance of SWI/SNF alterations in oncogenesis or tumor progression is being
increasingly acknowledged, as alterations in SWI/SNF subunits are found in over 20% of human
cancers [36]. Early preclinical studies suggested that SMARCA4-mutated tumors (such as non-small
cell lung cancers) were critically reliant on the SMARCA2 paralog [29,39]. Conversely, SCCOHT do not
seem amenable to this synthetic lethality strategy, given the complete loss of SMARCA2 expression
demonstrated in our series and in previous studies [22]. This loss of expression is not explained
by mutations in the coding sequence of SMARCA2. In an effort to explore the underpinnings of
SMARCA2 silencing, we report for the first time that homozygous polymorphisms at the two SMARCA2
promotor polymorphism sites (−741 bp and −1321 bp), previously linked to SMARCA2 silencing in
cancer [15,40], do not seem to be a recurrent event responsible for SMARCA2 silencing in SCCOHT.
Nevertheless, since most tumors in our study showed a heterozygous promotor polymorphism site
status, further explorations are warranted to elucidate whether heterozygous polymorphisms can
contribute to SMARCA2 silencing. In particular, in malignant rhabdoid tumor cell lines, increased
binding of epigenetic silencers HDAC9 and MEF2D at SMARCA2 promoter sites has been associated
with such heterozygous polymorphisms [41].
One case (IGR-03) from our series exhibited concomitant inactivating mutations in ARID1A and
ARID1B, two paralog DNA-binding subunits of SWI/SNF, but did not show SMARCA4 mutations.
This tumor was also the only case in which 19p CN-LOH was not present. Concomitant ARID1A/B
alterations occur in ~25% of dedifferentiated endometrial and ovarian carcinomas [42]. While case
IGR-03 could illustrate the challenges of differential diagnosis between SCCOHT and dedifferentiated
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ovarian carcinoma, another possibility is the existence of a molecular and morphologic overlap between
those two entities, both of which are characterized by a poorly differentiated, aggressive tumor and a
critically deregulated SWI/SNF complex.
Of note, one case (IGR-01) showed a p.Arg635* stop gain in the SMARCA1 gene in addition to a
deleterious SMARCA4 mutation. SMARCA1 encodes the ATP-ase of another chromatin remodeling
complex, ISWI, and is located on the X chromosome, suggesting that this alteration, which was seen at
an allele frequency of 0.37, could potentially carry a deleterious impact.
As a complement to the genomic findings, we also show for the first time
that SCCOHT are not characterized by SOX2 overexpression, contrary to another
aggressive SMARCA4/SMARCA2 double-negative malignancy—SMARCA4-deficient thoracic sarcoma
(SMARCA4-DTS). This emphasizes the existence of biological differences between SMARCA4-DTS
and SCCOHT, in addition to previously described discrepancies, such as higher genomic instability in
SMARCA4-DTS [26], and could have potential implications in diagnostic pathology.
In addition to SMARCA4 loss-of-function alterations, a few variants were seen in genes other than
SMARCA4, all localized in the 19p13.2-3 locus and subject to the CN-LOH event, for which a functional
impact could not be ruled out. In particular, the PLK5 p.G223V variant, predicted as potentially
damaging by the Polyphen-2 classifier, was found in 3/33 SCCOHT samples of the extended cohort.
The protein kinase domain of PLK5 is truncated in humans compared to mice, but the residual protein
containing the polo-box binding domain may act as a stress inducible tumor suppressor regulating G1
arrest [29]. Nevertheless, the relevance of these variants remains to be validated functionally.
Differential expression analysis comparing SCCOHT and benign ovarian tissue allowed to
nominate several genes potentially overexpressed in SCCOHT. Nevertheless, it must be kept in mind
that the bulk benign ovarian tissue used as the control in this analysis does not represent the exact
cell origin of SCCOHT, which remains unknown. Among other findings, we observed significant
overexpression of some putative therapeutic targets. Cancer-testis antigens have been proposed as
targets for immunotherapy approaches and Melanoma-associated antigen 4 (MAGEA4), which was
the most highly overexpressed gene in SCCOHT, is currently being investigated as a TCR-engineered
T-cell target (NCT03247309). The AURKB gene encodes Aurora B kinase, implicated in mitotic
progression, and may be targeted by pharmaceutical inhibitors (e.g., GSK1070916). The overexpression
of receptor tyrosine kinase genes, such as ERBB4 (HER4), could potentially be in line with a recent
study showing marked vulnerability of SCCOHT cells to multi-kinase inhibition [43]. Intriguingly,
SCCOHT also showed expression of neural differentiation markers and embryonic stem cell markers,
in keeping with what has previously been reported in malignant rhabdoid tumors [44]. Some of these
markers could represent treatment opportunities, such as the embryonic cell junction protein Claudin-6
(CLDN6), against which monoclonal antibodies were recently part of a clinical trial in ovarian cancers
(NCT02054351). Nevertheless, further studies are needed to confirm overexpression of these putative
treatment targets at the protein level and to validate their functional relevance in SCCOHT.
To further explore putative therapeutic approaches, we found that the SCCOHT cell line BIN67
was exquisitely sensitive to TSA and 5′-dAZAC, while cells with a SMARCA4 mutation and retained
SMARCA2 expression were resistant to these epigenetic therapies. In addition, we describe a clinically
meaningful response to single agent EZH2 inhibitor in a patient with SCCOHT, in keeping with what
has previously been demonstrated in vitro and in vivo [32]. Collectively, data from our series and from
previous studies suggest that SCCOHT tumors characterized by the loss of both SWI/SNF catalytic
subunits may be sensitive to treatment with HDAC, DNA methyltransferase and/or EZH2 inhibitors,
and that such strategies merit further investigation in this lethal disease.
Since SCCOHT often display initial chemosensitivity, but subsequently show rapid progression,
we compared the genomics of treatment-naïve (n = 3) versus chemotherapy-treated tumors (n = 3),
to uncover candidate resistance genes. Critically, neither the tumor mutation burden nor the somatic
copy number alterations were significantly increased in post-chemotherapy samples. The only
alterations seen in more than one post-chemotherapy sample and not in chemotherapy-naïve
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samples were ADGRV1 (one stop gain and one missense alteration) and FANCD2 (splice region
variants). Variants in ADGRV1, which encodes adhesion G protein-coupled receptor 1, were potentially
heterozygous, and the implication of this protein in cancer progression is unclear. Variants in
FANCD2 were predicted to be of low functional impact by the SnpEff tool. Although differential
expression analysis did not reveal any specific genes significantly deregulated between the two
groups, GSEA performed on the totality of ranked genes nominated several deregulated gene
expression programs, including an enrichment of genes related to eIF4E upregulation and a putative
downregulation of the KRAS pathway. Further studies comparing paired samples from the same
patient before and after treatment are needed to elucidate molecular underpinnings of treatment
resistance in SCCOHT. Nevertheless, our data suggest that it may rely on other mechanisms than
acquiring drug resistance mutations, contrary to what has been described in other tumor types.
5. Conclusions
SCCOHT are unique tumors. Despite their aggressive clinical course, they display genomic
stability, low mutation load, few SCNAs, and a remarkably homogeneous genomic profile. They are
almost universally characterized by a 19p CN-LOH, loss-of-function mutations in SMARCA4 and
concomitant loss of SMARCA2 expression. SCCOHT do not seem to acquire additional mutations after
exposure to chemotherapy. Some additional molecular alterations reported herein could be further
explored as therapeutic opportunities, such as the overexpression of putative therapeutic targets
(e.g., MAGEA4, AURKB or CLDN6). Our preliminary in vitro data and the reported patient case also
support the view that SCCOHT are sensitive to epigenetic modulators, such as HDAC, DNMT and
EZH2 inhibitors, in line with other studies and with early results of phase I trials, and warrant further
exploration of epigenetic treatment strategies in this lethal disease.
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